MWN110 / Minwei Biotech, Lepu Medical - LARVOL DELTA

Shanghai Minwei launches first human trial of ActRIIA/B antibody for obesity (AllSci Corp) - "The study (NCT07779980) is a randomized, double-blind, placebo-controlled single- and multiple-ascending-dose trial designed to enroll approximately 103 participants aged 18 to 65 years across sites in China. Part 1 includes eight single-dose cohorts ranging from 15 mg to 1,200 mg in healthy volunteers, while Part 2 evaluates multiple doses in participants with overweight or obesity, including two cohorts dosed weekly for five weeks and one cohort receiving two doses four weeks apart."

First-in-human • Trial status • Obesity

Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants (clinicaltrials.gov) - P1 | N=103 | Not yet recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P1 trial • Genetic Disorders • Obesity